1Li JJ, Kwak SJ, Jung DS, et al. Podocyte biology in diabetic nephropathy[J]. Kidney Int Suppl, 2007, 106:S36-S42.
2Wada J, Makino H. Inflammation and the pathogenesis of diabetic nephropathy[J]. Clin Sci (Lond), 2013, 124: 139-152.
3Jefferson JA, Shankland SJ, Pichler RH. Proteinuria in diabetic kidney disease: a mechanistic viewpoint[J]. Kidney Int, 2008, 74: 22-36.
4Wang G, Lai FM, Lai KB, et al. Urinary messenger RNA expression of podocyte- associated molecules in patients with diabetic nephropathy treated by angiotensin-converting enzyme inhibitor and angiotensin receptor blocker[J]. Eur J Endoerinol,2008, 158: 317-322.
5Cheng J, Zhang W, Zhang X, et al. Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis [J]. Clin J Am Soc Nephrol, 2012, 7: 391-400.
6Deb DK, Sun T, Wong KE, et al. Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes[J]. Kidney Int, 2010, 77: 1000-1009.
7He W, Kang YS, Dai C, et al. Blockade of Wnt/beta- catenin signaling by paricalcitol ameliorates proteinuria and kidney injury[J]. J Am Soc Nephrol, 2011, 22: 90-103.
8Deb DK, Chen Y, Zhang Z, et al. 1,25-Dihydroxyvitamin D3 suppresses high glucose-induced angiotensinogen expression in kidney cells by blocking the NF- {kappa}B pathway[J]. Am J Physiol Renal Physiol, 2009, 296: F1212-F1218.
9Ricardo SD, van Goor H, Eddy AA. Macrophage diversity in renal injury and repair[J], J Clin Invest, 2008, 118: 3522-3530.
10Eardley KS, Zehnder D, Quinkler M, et al. The relationship between albuminuria, MCP - 1/CCL2, and interstitial macrophages in chronic kidney disease[J]. Kidney Int, 2006, 69: 1189-1197.
